Bipolar Disorder

Uzedy, a once-monthly extended release long-acting injectable, is now FDA approved for bipolar I disorder.

Explore the complexities of aripiprazole in bipolar disorder treatment, including its efficacy and proper prescribing practices.

In clinical practice, there are individuals who have chronic low-grade hypomanic symptoms: high energy, need for less sleep than others, chronic optimism, and chronic risk-taking.

FDA approves Amneal Pharmaceuticals' new long-acting injectable risperidone for schizophrenia, enhancing treatment options and potentially patient adherence.

NRX-100, a preservative-free ketamine, is granted expanded access for treatment of suicidal ideation in depression, offering new hope for patients.

BioXcel Therapeutics reveals promising phase 3 results from the SERENITY trial, paving the way for potential at-home treatment of agitation in bipolar disorder and schizophrenia.

BioXcel Therapeutics advances BXCL501 for at-home treatment of agitation in bipolar disorders and schizophrenia, aiming for FDA approval by 2026.

BioXcel Therapeutics advances BXCL501 for outpatient treatment of agitation in bipolar disorder and schizophrenia, receiving positive FDA feedback in its pre-sNDA meeting discussion.

NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100, a preservation-free formulation of intravenous ketamine for suicidal ideation in depression.

Research reveals significant risks of neonatal complications linked to in utero valproic acid exposure, emphasizing the need for careful management during pregnancy.

Valproic acid poses significant risks during pregnancy, including congenital malformations and neurodevelopmental disorders, necessitating careful treatment planning.

BioXcel Therapeutics has submitted an pre-sNDA meeting package for Igalmi's outpatient use, aiming to enhance treatment options for agitation in bipolar disorders and schizophrenia.

Discover innovative strategies for early diagnosis and treatment of bipolar disorder, addressing challenges and exploring promising new therapies.

There is a critical link between sleep disorders and psychiatric conditions. In this Special Report, examine effective diagnosis and treatment strategies for better patient outcomes.

New research reveals the complex relationship between ADHD and bipolar disorder, highlighting genetic overlaps and treatment considerations for effective management.

Effective diagnosis and treatment of comorbid disorders in patients with bipolar enhance care and lead to more optimal mental health outcomes.

Combination therapy of TMS and ketamine could enhance brain perfusion and neuroplasticity.

Check out the pipeline updates from April!

The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treatment-resistant major depressive disorder has now demonstrated promise for reducing depressive symptoms of bipolar I disorder in an open-label feasibility and safety trial.

Adherence, switching, and quality of life are top concerns in BDI, and schizophrenia.

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

Although diagnostic criteria for a depressive episode are the same for unipolar major depression and bipolar depression, these episodes differ in their natural history.

Pipeline drug BHV-7000 failed to meet primary endpoint in a pivotal phase 2/3 trial for bipolar disorder; meanwhile, BHV-1300 sees success in sustained Reductions in Total IgG.

How should clinicians approach treatment when their patient disagrees with the diagnosis?